Safety and efficacy of cilostazol in the management of intermittent claudication

Yung-wei Chi, Carl J. Lavie, Richard V. Milani, Christopher J. White

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

Original languageEnglish (US)
Pages (from-to)1197-1203
Number of pages7
JournalVascular Health and Risk Management
Volume4
Issue number6
StatePublished - 2008
Externally publishedYes

Fingerprint

Intermittent Claudication
Safety
Peripheral Arterial Disease
Quality of Life
Therapeutics
Extremities
Pharmacokinetics
Exercise
Drug Therapy
cilostazol
Health
Pharmaceutical Preparations

Keywords

  • Cilostazol
  • Intermittent claudication
  • Peripheral arterial disease
  • Supervised exercise therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Safety and efficacy of cilostazol in the management of intermittent claudication. / Chi, Yung-wei; Lavie, Carl J.; Milani, Richard V.; White, Christopher J.

In: Vascular Health and Risk Management, Vol. 4, No. 6, 2008, p. 1197-1203.

Research output: Contribution to journalArticle

Chi, Yung-wei ; Lavie, Carl J. ; Milani, Richard V. ; White, Christopher J. / Safety and efficacy of cilostazol in the management of intermittent claudication. In: Vascular Health and Risk Management. 2008 ; Vol. 4, No. 6. pp. 1197-1203.
@article{73f43e4e0a6a488f8649b1482bca5293,
title = "Safety and efficacy of cilostazol in the management of intermittent claudication",
abstract = "Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.",
keywords = "Cilostazol, Intermittent claudication, Peripheral arterial disease, Supervised exercise therapy",
author = "Yung-wei Chi and Lavie, {Carl J.} and Milani, {Richard V.} and White, {Christopher J.}",
year = "2008",
language = "English (US)",
volume = "4",
pages = "1197--1203",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of cilostazol in the management of intermittent claudication

AU - Chi, Yung-wei

AU - Lavie, Carl J.

AU - Milani, Richard V.

AU - White, Christopher J.

PY - 2008

Y1 - 2008

N2 - Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

AB - Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

KW - Cilostazol

KW - Intermittent claudication

KW - Peripheral arterial disease

KW - Supervised exercise therapy

UR - http://www.scopus.com/inward/record.url?scp=60249088588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249088588&partnerID=8YFLogxK

M3 - Article

C2 - 19337533

AN - SCOPUS:60249088588

VL - 4

SP - 1197

EP - 1203

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 6

ER -